Evaluation of the Supporting Article: “Novel Anticoagulant Treatment for Pulmonary Embolism”

Paper Info
Page count 1
Word count 286
Read time 2 min
Topic Health
Type Annotated Bibliography
Language 🇺🇸 US

To support my PICOT question, I chose the article “Novel anticoagulant treatment for pulmonary embolism with direct oral anticoagulants phase 3 trials and clinical practice” by Tromeur et al. The purpose of the study presented in this paper is to show the superior efficacy and safety of direct oral anticoagulants (DOACs) for regular and extended treatment of VTE (Tromeur et al., 2018). This paper provides a short review of the article to determine its relevance and value of its findings.

The study aims to answer the question regarding the sufficiency of evidence regarding the advantages of the usage of DOACs. To do so, the authors present the assessment of the studies of DOACs that measure the effects of this treatment on patient mortality and clinically relevant bleeding incidents (Tromeur et al., 2018). The primary evidence points towards the fact that DOACs possess similar efficacy as Vitamin K antagonists (VKA) and low-molecular-weight heparin (LMWH) in the treatment of VTE (Tromeur et al., 2018). The study uses statistical evidence of the efficacy and safety of DOACs for patients with VTE in relation to VKA and LMWH. The authors combine the evidence of DOACs’ safety and efficacy from six trials that provide homogenous results, proving the authors’ hypothesis.

The data from the article is supported by multiple trials and proven by real-world studies that support the evidence from the tests (Tromeur et al., 2018). The findings of the article by Tromeur et al. imply that DOACs possess higher safety than conventional coagulants for both regular and extended treatment without losing any efficacy (Tromeur et al., 2018). The results from this article directly support the PICOT question of my study with high-level evidence gathered from trials of a substantial size.

Reference

Tromeur, C., Van der Pol, L. M., Mairuhu, A. T., Leroyer, C., Couturaud, F., Huisman, M., & Klok, F. (2018). Novel anticoagulant treatment for pulmonary embolism with direct oral anticoagulants phase 3 trials and clinical practice. Seminars in Interventional Radiology, 35(02), 83-91. Web.

Cite this paper

Reference

NerdyBro. (2022, August 25). Evaluation of the Supporting Article: “Novel Anticoagulant Treatment for Pulmonary Embolism”. Retrieved from https://nerdybro.com/evaluation-of-the-supporting-article-novel-anticoagulant-treatment-for-pulmonary-embolism/

Reference

NerdyBro. (2022, August 25). Evaluation of the Supporting Article: “Novel Anticoagulant Treatment for Pulmonary Embolism”. https://nerdybro.com/evaluation-of-the-supporting-article-novel-anticoagulant-treatment-for-pulmonary-embolism/

Work Cited

"Evaluation of the Supporting Article: “Novel Anticoagulant Treatment for Pulmonary Embolism”." NerdyBro, 25 Aug. 2022, nerdybro.com/evaluation-of-the-supporting-article-novel-anticoagulant-treatment-for-pulmonary-embolism/.

References

NerdyBro. (2022) 'Evaluation of the Supporting Article: “Novel Anticoagulant Treatment for Pulmonary Embolism”'. 25 August.

References

NerdyBro. 2022. "Evaluation of the Supporting Article: “Novel Anticoagulant Treatment for Pulmonary Embolism”." August 25, 2022. https://nerdybro.com/evaluation-of-the-supporting-article-novel-anticoagulant-treatment-for-pulmonary-embolism/.

1. NerdyBro. "Evaluation of the Supporting Article: “Novel Anticoagulant Treatment for Pulmonary Embolism”." August 25, 2022. https://nerdybro.com/evaluation-of-the-supporting-article-novel-anticoagulant-treatment-for-pulmonary-embolism/.


Bibliography


NerdyBro. "Evaluation of the Supporting Article: “Novel Anticoagulant Treatment for Pulmonary Embolism”." August 25, 2022. https://nerdybro.com/evaluation-of-the-supporting-article-novel-anticoagulant-treatment-for-pulmonary-embolism/.